Estrogen receptor in breast ductal carcinoma in situ: Good cop, bad cop?

Journal of Clinical Oncology

Volumn 30, Issue 12, 2012, Pages 1384-1386

  DeCensi, Andrea ^a,b   Pruneri, Giancarlo ^c   Guerrieri Gonzaga, Aliana ^b  

^a GALLIERA HOSPITAL   (Italy)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; AROMATASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; NUCLEAR RECEPTOR COACTIVATOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TAMOXIFEN; TUMOR MARKER;

CANCER GROWTH; CANCER INHIBITION; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; DUCTAL INTRAEPITHELIAL NEOPLASIA; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INTRADUCTAL CARCINOMA; INVASIVE CARCINOMA; MAMMOGRAPHY; POSTMENOPAUSE; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; RISK REDUCTION; SHORT SURVEY; SIGNAL TRANSDUCTION; SURVIVAL TIME; BREAST TUMOR; CANCER STAGING; CARCINOMA IN SITU; DISEASE FREE SURVIVAL; FEMALE; METABOLISM; MORTALITY; MULTIMODALITY CANCER THERAPY; PAGET NIPPLE DISEASE; PATHOLOGY; PREDICTIVE VALUE; REVIEW; RISK ASSESSMENT; SURVIVAL;

BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, DUCTAL, BREAST; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; RECEPTORS, ESTROGEN; RISK ASSESSMENT; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84862264813     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.40.7494     Document Type: Short Survey

References (25)

1. Tavassoli FA: Ductal carcinoma in situ: Introduction of the concept of ductal intraepithelial neoplasia. Mod Pathol 11:140-154, 1998
2. Cuzick J, Sestak I, Pinder SE, et al: Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: Long-term results from the UK/ANZ DCIS trial. Lancet Oncol 12:21-29, 2011
3. Wapnir IL, Dignam JJ, Fisher B, et al: Longterm outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst 103:478-488, 2011
4. Espina V, Liotta LA: What is the malignant nature of human ductal carcinoma in situ? Nat Rev Cancer 11:68-75, 2011
5. Musgrove EA, Sutherland RL: Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 9:631-643, 2009
6. Allred DC, Anderson SJ, Paik S, et al: Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: A study based on NSABP Protocol B-24. J Clin Oncol 30:1268-1273, 2012
7. Hammond ME, Hayes DF, Dowsett M, et al: American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28:2784-2795, 2010
8. Wang SY, Shamliyan T, Virnig BA, et al: Tumor characteristics as predictors of local recurrence after treatment of ductal carcinoma in situ: A meta-analysis. Breast Cancer Res Treat 127:1-14, 2011
9. Thorpe SM, Christensen IJ, Rasmussen BB, et al: Short recurrence-free survival associated with high oestrogen receptor levels in the natural history of postmenopausal, primary breast cancer. Eur J Cancer 29A:971-977, 1993
10. Guerrieri-Gonzaga A, Botteri E, Lazzeroni M, et al: Low-dose tamoxifen in the treatment of breast ductal intraepithelial neoplasia: Results of a large observational study. Ann Oncol 21:949-954, 2010
11. Bardou VJ, Arpino G, Elledge RM, et al: Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol 21:1973-1979, 2003
12. Lamy PJ, Pujol P, Thezenas S, et al: Progesterone receptor quantification as a strong prognostic determinant in postmenopausal breast cancer women under tamoxifen therapy. Breast Cancer Res Treat 76:65-71, 2002
13. Platet N, Cathiard AM, Gleizes M, et al: Estrogens and their receptors in breast cancer progression: A dual role in cancer proliferation and invasion. Crit Rev Oncol Hematol 51:55-67, 2004
14. Sanchez AM, Flamini MI, Zullino S, et al: Estrogen receptor - {alpha} promotes endothelial cell motility through focal adhesion kinase. Mol Hum Reprod 17:219-226, 2011
15. Yin W, Jiang Y, Shen Z, et al: Trastuzumab in the adjuvant treatment of HER2-positive early breast cancer patients: A meta-analysis of published randomized controlled trials. PLoS ONE 6:e21030, 2011
16. Cuzick J, Decensi A, Arun B, et al: Preventive therapy for breast cancer: A consensus statement. Lancet Oncol 12:496-503, 2011
17. Decensi A, Robertson C, Guerrieri-Gonzaga A, et al: Randomized double-blind 2 × 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in high-risk premenopausal women. J Clin Oncol 27:3749-3756, 2009
18. Irvin WJ Jr, Walko CM, Weck KE, et al: Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: A multicenter study. J Clin Oncol 29:3232-3239, 2011
19. Decensi A, Puntoni M, Pruneri G, et al: Lapatinib activity in premalignant lesions and HER-2- positive cancer of the breast in a randomized, placebo-controlled presurgical trial. Cancer Prev Res (Phila) 4:1181-1189, 2011
20. Solin LJ, Gray R, Baehner FL, et al: A quantitative multigene RT-PCR assay for predicting recurrence risk after surgical excision alone without irradiation for ductal carcinoma in situ (DCIS): A prospective validation study of the DCIS score from ECOG E5194. Cancer Res 71, 2011 (suppl 24; abstr 108s)
21. Haugan Moi LL, Hauglid Flågeng M, Gandini S, et al: Effect of low-dose tamoxifen on steroid receptor coactivator 3/amplified in breast cancer 1 in normal and malignant human breast tissue. Clin Cancer Res 16:2176-2186, 2010
22. Miller TW, Balko JM, Arteaga CL: Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. J Clin Oncol 29:4452-4461, 2011
23. Baselga J, Campone M, Piccart M, et al: Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med [epub ahead of print on December 7, 2011]
24. Namba R, Young LJ, Abbey CK, et al: Rapamycin inhibits growth of premalignant and malignant mammary lesions in a mouse model of ductal carcinoma in situ. Clin Cancer Res 12:2613-2621, 2006
25. Harris L, Fritsche H, Mennel R, et al: American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25:5287-5312, 2007